Document Detail


Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers.
MedLine Citation:
PMID:  15860969     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The use of beta blockers in congestive heart failure presents a therapeutic challenge for patients with acute episodes of decompensation. Such patients may be less responsive to positive inotropic agents, whereas the beneficial effects of nesiritide, which are not dependent on the beta-adrenergic receptor signal-transduction pathway, may be preserved. This analysis of the Vasodilation in the Management of Acute CHF trial evaluated the safety and efficacy of nesiritide in decompensated congestive heart failure patients receiving beta blockers. The Vasodilation in the Management of Acute CHF trial was a multicenter, randomized, controlled evaluation of nesiritide in 489 hospitalized patients with decompensated congestive heart failure. One hundred twenty-three patients were on chronic beta-blocker therapy at enrollment (31 randomized to placebo, 50 to nesiritide, and 42 to nitroglycerin). Primary end points included pulmonary capillary wedge pressure and dyspnea evaluation at 3 hours. Patients receiving nesiritide, but not IV nitroglycerin, had significantly reduced pulmonary capillary wedge pressure vs. placebo at 3 hours regardless of beta-blocker use. The use of beta blockers did not alter the beneficial effects of nesiritide on systemic blood pressure, heart rate, or dyspnea evaluation. In nesiritide-treated subjects, safety profiles were similar regardless of beta-blocker use. Thus, the clinical and hemodynamic benefits and safety of nesiritide are preserved in decompensated congestive heart failure patients receiving chronic beta blockade.
Authors:
William T Abraham; Mei L Cheng; Geraldine Smoluk;
Related Documents :
6111139 - The effect of beta blockade on the reaction of pressure and mesenteric flow to biogenic...
24844329 - Recurring pressure ulcers: identifying the definitions. a national pressure ulcer advis...
3023779 - The effect of acute and chronic administration of timolol on cardiac sympathetic neural...
2740149 - Beta-adrenergic influence on increased myocardial oxygen consumption during hypoxemia i...
22848069 - Excessive wave reflections on admission predict post-discharge events in patients hospi...
8832309 - Quality of life before and during antihypertensive treatment: a comparative study of ce...
16378009 - Intraocular pressure measurement-comparison of dynamic contour tonometry and goldmann a...
11873089 - Group- and sex-specific effects of age, body composition and pulse rate on blood pressu...
14595519 - Early escharotomy as a measure to reduce intraabdominal hypertension in full-thickness ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Congestive heart failure (Greenwich, Conn.)     Volume:  11     ISSN:  1527-5299     ISO Abbreviation:  Congest Heart Fail     Publication Date:    2005 Mar-Apr
Date Detail:
Created Date:  2005-04-29     Completed Date:  2005-08-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9714174     Medline TA:  Congest Heart Fail     Country:  United States    
Other Details:
Languages:  eng     Pagination:  59-64     Citation Subset:  IM    
Affiliation:
Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH 43210-1252, USA. abraham-1@medctr.osu.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use*
Double-Blind Method
Female
Heart Failure / drug therapy*,  physiopathology
Hemodynamics / drug effects
Humans
Injections, Intravenous
Male
Middle Aged
Natriuretic Agents / therapeutic use*
Natriuretic Peptide, Brain / therapeutic use*
Nitroglycerin / administration & dosage,  therapeutic use
Pulmonary Wedge Pressure / drug effects
Safety
Time Factors
Vasodilation / drug effects
Vasodilator Agents / administration & dosage,  therapeutic use
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Natriuretic Agents; 0/Vasodilator Agents; 114471-18-0/Natriuretic Peptide, Brain; 55-63-0/Nitroglycerin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gynecomastia and hypertension.
Next Document:  Brain natriuretic peptide and diastolic dysfunction in the elderly: influence of gender.